Modified high-dose melphalan and autologous SCT for AL amyloidosis or high-risk myeloma: analysis of SWOG trial S0115

Por Sanchorawala, V, Hoering, A, Seldin, DC, Finn, KT, Fennessey, SA, Sexton, R, Mattar, B, Safah, HF, Holmberg, LA, Dean, RM, Orlowski, RZ, Barlogie, B
Publicado em 2013